Back to Search
Start Over
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2018 Jul 15; Vol. 57 (14), pp. 2007-2011. Date of Electronic Publication: 2018 Feb 28. - Publication Year :
- 2018
-
Abstract
- A 45-year old woman who underwent several surgeries for tumors associated with von Hippel-Lindau disease (VHL) was referred to our hospital due to a pancreatic tumor and liver tumors. She was diagnosed with pancreatic neuroendocrine tumor (NET) with a Ki67 index of 40% based on the examination of a biopsy specimen of the liver tumors. She was treated with everolimus for 6 months and sunitinib for 6 weeks as first- and second-line therapies. She survived for 13 months. At autopsy the diagnosis of pancreatic neuroendocrine tumor (NET)-G3 was confirmed. We herein report an aggressive clinical course of VHL-related NET G3. The further accumulation of cases is required to reach a consensus on treatment for this disease.
- Subjects :
- Asian People
Carcinoma, Neuroendocrine etiology
Carcinoma, Neuroendocrine physiopathology
Female
Humans
Liver Neoplasms etiology
Liver Neoplasms physiopathology
Middle Aged
Pancreatic Neoplasms etiology
Pancreatic Neoplasms physiopathology
Sunitinib
Treatment Outcome
von Hippel-Lindau Disease physiopathology
Antineoplastic Agents therapeutic use
Carcinoma, Neuroendocrine drug therapy
Everolimus therapeutic use
Indoles therapeutic use
Liver Neoplasms drug therapy
Pancreatic Neoplasms drug therapy
Pyrroles therapeutic use
von Hippel-Lindau Disease complications
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 57
- Issue :
- 14
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 29491307
- Full Text :
- https://doi.org/10.2169/internalmedicine.0416-17